7/21/2022 9:46:17 AM
Wedbush Reiterates SUTRO BIOPHARMA INC (STRO) At Outperform With $20 Price Target
12/27/2021 7:06:15 AM
KOL Virtual Event To Provide Dose Expansion Data For Antibody-Drug Conjugate Program For Advanced Ovarian Cancer
12/27/2021 7:03:37 AM
Sutro Biopharma, Tasly Biopharma Enter Into Exclusive License Agreement For STRO-002 In Greater China
11/17/2021 7:09:50 AM
Sutro Biopharma Appoints Heidi Hunter To Board
11/10/2021 7:14:59 AM
Sutro Biopharma Q3 Loss Per Share $0.67 Vs Profit $0.45 Last Year
9/16/2021 7:05:24 AM
Sutro Biopharma Names Nicole Chieffo VP Of Clinical Operations And Werner Rubas VP Of Preclinical Development
8/18/2021 7:13:46 AM
Sutro Biopharma Reports STRO-002 FDA Fast Track Designation For Patients With Advanced Ovarian Cancer
8/9/2021 7:38:15 AM
Sutro Biopharma Q2 Net Loss $6.1 Mln Vs. Net Profit $29.9 Mln Last Year
5/7/2021 7:49:34 AM
Sutro Biopharma Q1 Loss Per Share $0.66 Vs Loss Per Share $0.84 Last Year
4/15/2021 7:26:27 AM
Sutro Biopharma Earns$15 Mln Milestone Payment From Cytokine Derivatives Collaboration With Merck
1/21/2021 7:11:50 AM
Sutro Biopharma : First Patient Dosed In Dose-Expansion Study Of STRO-002 In Patients With Ovarian Cancer
4/2/2019 7:11:26 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) Q4 19 Rev. Estimate To 11.3 M From 23.8 M
4/2/2019 7:11:13 AM
Wedbush Is Cutting SUTRO BIOPHARMA INC (STRO) Q3 19 Rev. Estimate To 11.3 M From 13.8 M
4/2/2019 7:11:00 AM
Wedbush Is Increasing SUTRO BIOPHARMA INC (STRO) Q2 19 Rev. Estimate To 11.3 M From 3.8 M
4/2/2019 7:10:51 AM
Wedbush Is Increasing SUTRO BIOPHARMA INC (STRO) Q1 19 Rev. Estimate To 11.3 M From 3.8 M